DOI: 10.1161/CIRCULATIONAHA.117. 030578 Functional testing (FT) for patients with chest pain has been a preferred method for evaluation of coronary artery disease (CAD) during decades. Current guidelines recommend FT to risk stratify and identify patients with ischemia prior to invasive coronary angiography (ICA). However, as lower probability patients are being referred, the prognostic and diagnostic accuracy of FT has declined. 1, 2, 3 Rozanski et al demonstrated that the prevalence of abnormal single photon emission computed tomography studies declined from 41% to only 9% over two decades. 4 A lower pre-test probability being tested may have led to poorer performance of FT, especially for diagnosis of obstructive CAD. Currently, a majority of patients who undergo ICA after FT have non-obstructive CAD or normal coronary arteries, confirming a low diagnostic accuracy in current clinical practice. 5 Of the patients enrolled in the National Cardiovascular Data Registry who had positive stress tests, 59% were found to have normal or non-obstructive disease at the time of ICA, slightly better than the 65% negative rate of those receiving ICA without stress testing prior. 6 In another National Cardiovascular Data Registry analysis of 302,651 single photon emission computed tomography studies, only 134,670 (44.4%) had obstructive disease at ICA. 5 Exercise treadmill testing, stress echocardiography and magnetic resonance imaging also yielded very low (44-45%) rates of obstructive CAD at time of ICA. This performance of FT in current practice calls for evaluation of alternative strategies for the initial work-up of patients who are presently at lower risk for myocardial ischemia and who have very low event rates given contemporary care. 7 These alternative strategies could also include no testing.
Coronary artery calcium (CAC) is low cost (typically <$100) and low radiation (<1 milliSievert) test, which allows direct visualization of coronary atherosclerosis without needles, contrast or injection. 8 According to the most recent American Heart Association (AHA) 9 and
American College of Cardiology Foundation (ACCF)/AHA 10 guidelines, CAC has Class IIA and IIB recommendations for assessing risk in intermediate and low-to-intermediate asymptomatic patients, respectively, and in guiding management of hyperlipidemia. 11 Studies also indicate that CAC may accurately risk stratify both low risk stable patients with new onset chest pain 12,13 and those presenting to the emergency department with acute chest pain, and has a Class IIB recommendation for use in symptomatic individuals. 9, 14 It should be noted that CAC does not test for obstructive disease or functional ischemia, but rather is a surrogate for coronary atherosclerotic plaque burden. A low plaque burden in symptomatic individuals has been shown to be associated with a low risk state, and has been used for symptomatic individuals to predict a low risk state with absent or minimal CAC. However, most studies of CAC in symptomatic patients were limited by a relatively small numbers of patients and limited follow-up. No large scale or randomized study has evaluated the utility or prognostic ability of CAC in stable CAD compared to FT.
The Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial has published on the prognostic implications of functional testing compared to coronary computed tomographic angiography (CTA). 7, 15 We have recently published a sub-study of PROMISE comparing coronary CTA vs FT. 16 Coronary CTA, by visualizing non-obstructive CAD, identifies additional at-risk patients and imparts better prognostic and discriminatory information than FT. Here we present unique data evaluating prognostic data related to CAC in the PROMISE trial. We hypothesize that coronary atherosclerosis burden, as determined by CAC, will be a robust predictor of major adverse cardiovascular events (MACE). We sought to evaluate the comparative prognostic ability of FT to CAC in a large cohort of symptomatic lowintermediate risk patients. For the FT group, we excluded patients whose test results could not be assigned to prespecified test strata due to indeterminate test results, including patients who underwent FT with exercise but achieved less than 75% of maximum predicted heart rate. The flow of patients is described in Figure 1 .
Methods

Study Design and Population
Study Procedures: After providing written informed consent, participants were randomly assigned to either the anatomic or the FT group, with stratification according to study site and according to the choice, as indicated before randomization by the site clinician, of the intended FT if the patient were to be assigned to that study group. 7 
Statistical Analysis
Descriptive statistics are presented as mean and standard deviation for continuous variables and absolute and relative frequencies for categorical variables. Cumulative event rates based on test results were computed for each testing strategy (CAC and FT) using the method of Kaplan and Meier. 18 Cox proportional hazards regression models were used to compute hazard ratios and 95% confidence intervals regarding the relationship of test results to the time to the first clinical event (or censoring) for each composite endpoint. 19 To appropriately account for heterogeneity among the subjects, analyses were adjusted for a prespecified set of baseline covariates, including age, sex, CAD risk equivalent (history of either diabetes mellitus, peripheral artery disease, or cerebrovascular disease), and the prespecification of the intended FT (if randomly assigned to the FT arm). Proportional-hazards assumption were tested on the basis of Schoenfeld residuals. To evaluate the predictive power of the Cox regression models we computed Harrell's C (C-statistic). 20, 21 Analyses were performed for the primary, secondary, and tertiary endpoints.
All P-values are 2-sided, and were considered significant if < 0.05. All analyses were performed using Stata, version 14.2 (StataCorp, College Station, Texas).
Results
Of the patients included, 4,209 received CAC testing, and 4,602 received FT. The baseline demographics and risk factors are outlined in Table 2 . There were no clinically meaningful differences in baseline patient demographics, cardiovascular risk, medication, or clinical presentation between CAC and FT patients (Table 2) . Overall, patients were on average 61 years of age, slightly more than 50% were women, 78% were white, and the combined Diamond- (Table 3 ).
An abnormal FT was significantly more specific for predicting events (78.6% for FT vs 35.2%
for CAC, p<0.001) (Supplemental Table 1 ). Increasing the CAC cutpoint improves specificity, at an expense of sensitivity. A cutpoint of ≥100 increased specificity to 67%, while reducing sensitivity to 61%, and a CAC cutpoint of >400 revealed a specificity of 85%, while lowering sensitivity to 31%.
Testing and Outcomes
Increasing CAC scores were associated with increasing risk of MACE. A zero CAC score was associated with a very low event rate (21/1,457, 1.4%). Event rates (MACE) increased with increasing CAC scores, with scores 100-400 associated with a 5.2% event rate, increasing to 6.4% (41/640) in those with scores >400 (Table 3) . A normal FT was associated with a 2.1% event rate (75/3588) increasing to 9.6% in those with severe abnormalities. Similar results were found if events were defined as cardiovascular death/myocardial infarction/unstable angina or cardiovascular death/myocardial infarction ( Figure 2 ). 
Distribution of Events based on CAC and FT abnormalities.
Discriminatory Ability
Based on this result, we further characterized the test results of patients who did not have an abnormal test defined as significant CAC (≥100) (n=2,797) or myocardial ischemia (n=4,020). CAC scanning identified 47.9% (n=1340/2797) of patients as having mild CAC (defined as score 1-99) and a minority of events occurred in these patients (23.3%, n=31/133) ( Varying the cutpoints of CAC did not significantly alter the relationships with events (Supplemental Tables 2-3) . Defining a CAC ≤10 as normal did not change the significant prediction of CAC>10 for cardiovascular events (HR 2.42 (1.56-3.76), p<0.001) ( Table 4 ).
There was no significant difference for any endpoint in stratifying by CAC = 0 or defining low risk as CAC <10. Similarly, defining severe CAC as >300 (as defined in the ACC/AHA risk assessment guidelines 5 ) led to similar predictive power for events (HR 1.94 (1.32-2.86), p<0.001) ( Table 4) . .001]). In regards to obstructive disease, this study revealed that of those with zero CAC (n=1,457), only 22 had stenosis ≥50% (Table 5 ). Of those with CAC=0, only 7
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(0.5%) had >70% stenosis , 15 had 50-70% (1.0%) and 241 (14.7%) had non-obstructive stenosis, and 1,177 (80.8%) had normal coronary arteries (zero stenosis) on coronary CTA.
Discussion
The optimal diagnostic evaluation of patients suspected of having obstructive CAD remains unclear. Given the low prevalence of CAD and excellent prognosis of symptomatic patients with contemporary care, we sought to evaluate whether CAC might provide more robust prognostic information in this cohort as it does in asymptomatic populations. The results of this study demonstrate that CAC can robustly predict events in symptomatic persons (HR 2.0-4.7) with similar results to FT. The study establishes, for the first time in a large prospective trial, the ability of CAC zero to predict very low rate of future events in symptomatic patients, and more importantly, the safety of a zero score to exclude future cardiovascular events. 22 While stress testing demonstrated a low sensitivity for cardiovascular events (48%), the specificity was significantly higher than for CAC testing, especially using a definition of CAC>0
as the threshold. CAC may have several advantages over FT. When compared to FT, CAC is a more rapid, simple test which has no contraindications, is performed on conventional CT systems, incurs little radiation exposure, is easily interpretable and relatively inexpensive. 30 Given the low prevalence of obstructive CAD in the current populations, the optimal diagnostic strategy may be CAC as an initial test, followed by a second test. Thus the high sensitivity of CAC for cardiovascular events could potentially be used to rule out patients, and in those with positive CAC scans, a second test with high specificity could be used to determine those at risk of future cardiovascular events. FT is an ideal candidate for such a second test as it provides evidence of ischemia required to guide revascularization. Furthermore, in the PROMISE Trial,
The CT strategy was associated with a higher proportion of patients newly initiated on aspirin (51% increase), statins (110% increase), and beta-blockers (52% greater), compared to FT (P<.0001 for each) and the patients reporting healthy eating was also higher after coronary CTA (p=0.002). 31 The SCOT-Heart trial also reported more preventive therapies in the CTA arm. 
0001). CRESCENT investigators concluded that
"Incorporating the calcium scan into the diagnostic workup was safe and lowered diagnostic expenses and radiation exposure." In this study, there was no significant difference in stratifying by CAC = 0 or defining low risk as CAC <10 (Tables 3 and 4 ). In PROMISE, 19 of 21 patients with zero CAC and cardiovascular events had <70% stenosis on coronary CTA, and hard event rates for CAC zero were far less than 1% annual risk. In the cardiovascular death/MI group, there were only 9 events among the 1,457 patients followed with CAC 0. In regards to obstructive disease, this study revealed that of those with zero CAC (n=1,457), only 7 (0.5%) had >70% stenosis on CTA (Supplemental Table 4 ). This very high sensitivity for obstructive disease and cardiovascular events supports use of a CAC first approach as was done in CRESCENT, using CAC to exclude further evaluation.
While CTA has been demonstrated to have higher discriminatory ability than both CAC and FT (Table 5) .
Limitations
This analysis represents a post-hoc evaluation of CAC testing, as the design of the PROMISE Trial was CTA versus FT. 14 Furthermore, only 4,209 patients underwent CAC scanning, while 4,589 underwent CTA testing in PROMISE. 16 The reason not all patients underwent CAC scanning with CTA is because this was set up as a pragmatic design, and the exact protocol for CTA was not pre-specified but left to the local imaging expert (radiologist or cardiologist 
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